Uma revisão entre 1980 -2000". A inibição da Enzima Conversora da Angiotensina (ECA) é um alvo terapêutico moderno e efi caz no tratamento da hipertensão arterial. Na cascata enzimática que envolve o sistema renina-angiotensina, a ECA promove a remoção dos aminoácidos histidilleucina da angiotensina I para formar o octapeptídio angiotensina II, a qual é fi siologicamente ativa em diversos sistemas, e considerado como um dos mais potentes vasoconstrictores endógenos conhecido. Portanto, uma racionalidade no tratamento da hipertensão seria administrar drogas ou compostos de origem natural que inibam seletivamente a ECA. O presente estudo constitui uma revisão da literatura sobre plantas e moléculas de origem natural com potencial anti-hipertensivo, baseado na inibição in vitro da ECA. A revisão referencia 321 plantas, partes usadas, tipo de extrato e se é ativo ou não. Inclui ainda o nome de 158 compostos isolados de plantas superiores, esponjas e algas marinhas, fungos e venenos de cobra. Alguns aspectos de pesquisa recente com produtos naturais direcionados à produção de drogas anti-hipertensivas também são discutidos. Nesta revisão 148 referências foram consultadas.
INTRODUCTION
The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure defi nes hypertension as systolic blood pressure (SBP) of 140 mm Hg or greater, diastolic blood pressure (DBP) of 90 mm Hg or greater, or taking anti-hypertensive medication. The objective of identifying and treating high blood pressure is to reduce the risk of cardiovascular disease and associated morbidity and mortality. To that end, it is useful to provide a classifi cation of adult blood pressure for the purpose of identifying high-risk individuals and to provide guidelines for treatment. The positive relationship between SBP and DBP and cardiovascular risk has long been recognized. This relationship is strong, continuous, graded, consistent, independent, predictive, and etiologically signifi cant for those with and without coronary heart disease (Stamler, 1991 , Flack et al., 1995 . Therefore, although classifi cation of adult blood pressure is somewhat arbitrary, it is useful to clinicians who must make treatment decisions based on a verifi cation of factors including the actual level of blood pressure. Hypertension detection begins with proper blood pressure measurements. Repeated blood pressure measurements will determine whether initial elevations persist and require prompt attention or have returned to normal. According to the National Heart, Lung and Blood Institute (1997) , heart disease and stroke remain the fi rst and third leading causes of death, respectively, in the United States and impose an enormous fi nancial and social burden on Americans. In particular, the continued high prevalence of hypertension and hypertension-related complications of stroke, heart failure, and end-stage renal disease in the southeastern United States makes these diseases a public health concern for all who reside in this region, particularly African Americans (Hall et al., 1997) . Approximately 50 million adult Americans have hypertension and are still unaware that they have high blood pressure (Burt et al., 1995) . In addition, most persons with hypertension have additional risk factors for cardiovascular disease (Furster; Pearson, 1996) . Thus, prevention and treatment of hypertension and target organ disease remain important public health challenges that must be addressed as we enter the new millennium.
There are different way to treat the problem related to arterial hypertension. Treatment leading to lower levels may be useful, particularly to prevent stroke (Du et al., 1997) , to preserve renal function (Lazarus et al., 1997) and to prevent or slow heart failure progression (Krumholz et al., 1997 , Neaton et al., 1993 . The goal may be achieved by lifestyle modifi cation, alone or with pharmacological treatment.
Non-Pharmacological treatment of arterial hypertension
The main objective of hypertensive treatment is to reduce the high morbidity and mortality. As well as reducing the pressure, an important objective of treatment is to control other cardiovascular risk factors. Lifestyle modifi cations offer the potential for preventing hypertension, have been shown to be effective in lowering blood pressure, and can reduce other cardiovascular risk factors at little cost and with minimal risk (Appel et al., 1997) . Even when lifestyle modifi cations alone are not adequate in controlling hypertension, they may reduce the number and dosage of anti-hypertensive medications needed to manage the condition (Neaton et al., 1993 , Singer et al., 1995 .
Pharmacological treatment of arterial hypertension
Reducing blood pressure with drugs clearly decreases cardiovascular morbidity and mortality. Protection has been demonstrated for stroke, coronary events, heart failure, progression of renal disease, progression to more severe hypertension, and all-cause mortality (Psaty et al., 1997, Moser; Hebert, 1996) .
Actually, there are a lot of alternatives available to treat arterial hypertension, both in schemes of monotherapy and/or combined therapy. The effi cacy, security and effects of the different drugs are fundamental criteria to be considered in choosing the antihypertensive treatment scheme for each patient. In Table  1 the conventional pharmacological anti-hypertensive medications are presented, further details see references.
Mechanism of anti-hypertensive effect based on the inhibition of the angiotensin converting enzyme (ACE)
The renin-angiotensin-aldosterone system plays a pivotal role in the maintenance of vascular tone vis à vis peripheral resistance. Renin produced from the juxtaglomerular apparatus of the kindney, splits angiotensinogen to produce the inactive decapeptide angiotensin I. The latter is then converted to the powerful octapeptide vasoconstrictor, angiotensin II by the action of angiotensin converting enzyme (ACE). Angiotensin II also stimulates the synthesis and release of aldosterone from the adrenal cortex, which increases blood pressure by promoting sodium retention (and thereby water retention) in the distal tubules (Ahnfelt-Ronne, 1991) . Research suggests that angiotensin II stimulates the production of superoxide anion and hydrogen peroxide in the polymorphonuclear leucocytes, which inactivates the vasodilatory compounds endothelial derived vascular relaxing factor (nitric oxide -NO) and prostacyclin (PGI 2 ) (Kumar; Das, 1993) . ACE also inactivates the vasodilating nonapeptide bradykinin, which theoretically contributes to the hypertensive effects of ACE activity (Ahnfelt-Ronne, 1991) (Figure 1 ). Therefore, a good rationale for treating hypertension would be to administer drugs or natural compounds which selectively inhibit ACE. Such selective inhibitors would be capable of decreasing blood pressure and producing natriuresis and diuresis.
In a previous paper this research group has reviewed crude plant extracts and chemically defi ned molecules with potential antitumor activity for mammary (Moura et al., 2001 ), cervical (Moura et al., 2002 and Main lifestyle modifi cations for hypertension prevention and management.
Main Lifestyle Modifications -Lose weight if overweight. -Limit alcohol intake -Increase aerobic physical activity -Reduce sodium intake to no more than 100 mmol per day -Maintain adequate intake of dietary calcium and magnesium for general health -Stop smoking -Reduce intake of dietary saturated fat and cholesterol for overall cardiovascular health.
ovarian neoplasias (Silva et al., 2003) , as inhibitors of HMG CoA reductase (Gonçalves et al., 2000) , central analgesic activity (Almeida et al., 2001) , employed in prevention of osteoporosis (Pereira et al., 2002) , for the treatment of Parkinson's disease (Morais, 2003 ), with antileishmanial (Rocha et al., 2005 , hypoglycemic (Barbosa-Filho et al., 2005) , antiinfl ammatory activity (Falcão et al., 2005 , Barbosa-Filho et al., 2006a and inhibitors of the enzyme acetylcholinesterase (BarbosaFilho et al., 2006b) .
In this work we present such natural products, in other words, plant extracts, semi purifi ed fractions, chemically defi ned molecules isolated from plants and metabolites from fungi that act specifi cally inhibiting the angiotensin converting enzyme (ACE), which is one of the most powerful known vasoconstrictors.
MATERIAL AND METHODS
The keyword for this revision was ACE (Angiotensin Converting Enzyme). We made a data search in the Chemical Abstracts, Biological Abstracts and the NAPRALERT (trademark, NAtural PRoducts ALERT) database at the Illinois University, Chicago. The specialized magazines referenced were than searched. 
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RESULTS AND DISCUSSION
Plants which inhibit the angiotensin converting enzyme
Screening for anti-hypertensive effects in traditional medicines has been performed over many years and several animal models have been used (Villar et al., 1986) . In western medicine, drug development has become increasingly more mechanistic in focus with the aim of excluding unwanted side-effects. The rationale behind this approach is to identify a molecular target (receptor or enzyme) which has an essential role in the regulation of the disease and then search for ligands, substrates or inhibitors of the target.
In the treatment of hypertension, inhibition of the angiotensin converting enzyme (ACE) is established as a modern therapeutic principle. Elbl and Wagner (1991) introduced an in vitro assay for the detection of ACE inhibitors in plant extracts. This method is based on the ACE-catalyzed cleavage of the chromophore-fl uorophore labelled substrate, dansyltriglycine, into dansylglycine, which is quantitatively measured by HPLC (high performance liquid chromatography). By using this technique, a number of plant species have been found to be active (Elbl; Wagner, 1991) . Williams et al. (1997) using another bioassay, but also involving ACE inhibition, verifi ed that the leaves and stems of Euphorbia hirta inhibited the activity of angiotensin converting enzyme by 90% and 50% at 500 μg and 150 μg respectively using enzyme linked immunosorbent assay (ELISA). The data are presented in Table 2 . The study also revealed that the most active ACE inhibitory compounds were present in the polar and very polar fractions of the medium.
The results of the literature survey are presented in Table 3 , which lists the effects on angiotensin converting enzyme of 321 plant extracts. The plants are arranged in alphabetical order. Each entry gives the following information in sequence: botanical name, family, part used, type of extract or fraction, whether active or not and reference.
From these studies, is appears to be the possibe, using biomonitored phytochemical methods, to fi nd out new substances potentially active, which may prove important for the development of new substances inhibitors of the angiotensin converting enzyme.
Chemically defi ned molecules inhibitors of the angiotensin converting enzymes
Synthetic drugs such as captopril (Ondetti et al., 1977) or teprotide (Ferreira, 1965) , a nonapeptide isolated from the venom of Bothrops jararacussu with established ACE inhibiting activity are used as fi rst line drugs in both secondary and primary hypertension. The rising cost of these and other imported anti-hypertensive drugs stimulates the evaluation of new products as a source of cheaper agents. Several classes of ACE inhibitory compounds were isolated from plants, for example, fl avonoids (Wagner et al., 1991; Elbl, 1992; Hansen et al., 1996b) , xanthones (Chen et al., 1992) , secoiridoids (Hansen et al., 1996a) . For a comprehensive review of these compounds, see Hansen (1995) .
The results of the literature are presented in Table 4 , which lists the effects on angiotensin converting enzyme of 158 chemically defi ned molecules. The compounds are arranged in alphabetical order. Each entry gives the following information in sequence: chemical name, class, whether active or not and reference.
CONCLUSION
This revision focussed initially on the search for information about natural product inhibitors of the angiotensin converting enzyme (ACE). From the literature searched, 321 species of plants and 158 natural substances which inhibit ACE were identifed. These natural products may become important for human clinical treatments. 18.2 ± 2.5 43.7 ± 4.5 48.6 ± 0.9 45.4 ± 1.8 Han et al., 1991 Oh et al., 1997 Hansen et al., 1995 Hansen et al., 1995 Hansen et al., 1995 Crataegus sp. 
